Content validity of the Migraine-Specific Quality of Life Questionnaire version 2.1 electronic patient-reported outcome

Speck, Rebecca M.; Shalhoub, Huda; Ayer, David; Ford, Janet H.; Wyrwich, Kathleen W.; Bush, Elizabeth Nicole

doi:10.1186/s41687-019-0138-x

Cited by 13 publications

(12 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It simply requires a few seconds to remember" [62]. Participants indicated recall accuracy as a concern only for recall periods greater than one week (e.g., 4 weeks [63]).…”

Section: I) Duration Should Capture Important Effectsmentioning

confidence: 99%

Systematic Review of the Effect of a One-Day Versus Seven-Day Recall Duration on Patient Reported Outcome Measures (PROMs)

Peasgood

Caruana

Mukuria

2023

Patient

View full text Add to dashboard Cite

Background There is ongoing uncertainty around the most suitable recall period for patient-reported outcome measures (PROMs). Method This systematic review integrates quantitative and qualitative literature across health, economics, and psychology to explore the effect of a one-day (or '24-h') versus seven-day (or 'one week') recall period. The following databases were searched from database inception to 30 November 2021: MEDLINE, EMBASE, PsycINFO, Web of Science, EconLit, CINAHL Complete, Cochrane Library, and Sociological Abstracts. Studies were included that compared a one-day (or '24-h') versus seven-day (or weekly) recall period condition on patient-reported scores for PROM and Health-Related Quality-of-Life (HRQoL) instrument scores in adult populations (aged 18 and above) or combined paediatric and adult populations with a majority of respondents aged over 18 years. Studies were excluded if they assessed health behaviours only, used ecological momentary assessment to derive an index of daily recall, or incorporated clinician reports of patient symptoms. We extracted results relevant to six domains with generic health relevance: physical functioning, pain, cognition, psychosocial wellbeing, sleep-related symptoms and aggregated disease-specific signs and symptoms. Quantitative studies compared weekly recall scores with the mean or maximum score over the last seven days or with the same-day recall score. Results Overall, across the 24 quantitative studies identified, 158 unique results were identified. Symptoms tended to be reported as more severe and HRQoL lower when assessed with a weekly recall than a one-day recall. A narrative synthesis of 33 qualitative studies integrated patient perspectives on the suitability of a one-day versus seven-day recall period for assessing health state or quality of life. Participants had mixed preferences, some noted the accuracy of recall for the one-day period but others preferred the seven-day recall for conditions characterised by high symptom variability, or where PROMs concepts required integration of infrequent experiences or functioning over time. Conclusion This review identified a clear trend toward higher symptom scores and worse quality of life being reported for a seven-day compared to a one-day recall. The review also identified anomalies in this pattern for some wellbeing items and a need for further research on positively framed items. A better understanding of the impact of using different recall periods within PROMs and HRQoL instruments will help contextualise future comparisons between instruments. Plain English SummaryQuestionnaires ask patients about their health over different time periods (e.g., "what were your symptoms like over the last week?" versus "what were your symptoms like today?"). Studies find that people may report their symptoms as more severe when they are asked to think about their symptoms over the last week compared to the last day. Understanding how different time periods influence patient responses will allow researchers to compar...

show abstract

“…It simply requires a few seconds to remember" [62]. Participants indicated recall accuracy as a concern only for recall periods greater than one week (e.g., 4 weeks [63]).…”

Section: I) Duration Should Capture Important Effectsmentioning

confidence: 99%

Systematic Review of the Effect of a One-Day Versus Seven-Day Recall Duration on Patient Reported Outcome Measures (PROMs)

Peasgood

Caruana

Mukuria

2023

Patient

View full text Add to dashboard Cite

show abstract

“…The present study evaluated for the first time the features of single migraine attacks in patients treated with OBT-A, who used an innovative method to report the severity of acute symptoms in real-time [12].…”

Section: Discussionmentioning

confidence: 99%

“…A smartphone app named Aid Diary was specifically designed for this study, by Terin Consortium () It was built to be easy to use, with an obligatory sequence of questionnaires to tick in order to send a complete report; the questionnaires presented in order are: Visual Analogue Scale (VAS) for pain (Figure 2), Allodynia Questionnaire [8,13,18,19], a list of vegetative symptoms associated with migraine attack (nausea, vomiting, phono-photophobia) [11,12], and an image of the head, neck and other parts of the body, in frontal and posterior view, where the patient had the possibility to click exactly on the sites where he/she perceived the pain, to render a report of the extension of headache according to precise and predetermined coordinates (Figure 3). For allodynia, 12 total symptoms were reported, in accordance with previous studies [8,13,18,19], so the final score between 0 and 12 indicated the number of acute allodynia features.…”

Section: Methodsmentioning

confidence: 99%

Effects of Botulinum Toxin on Migraine Attack Features in Chronic Migraine: A Six-Month Open-Label Observation Study through Electronic Diary Smartphone Application

Santoro

Delussi

Leone

et al. 2019

Toxins

View full text Add to dashboard Cite

OnobotulintoxinA (OBT-A) is a treatment option for Chronic Migraine (CM). It works on central sensitization and pain but its mode of action is still unknown. To observe how OBT-A treatment works on single migraine attacks, this paper covers an over-6-month observation period through self-reported smartphone application data. This was an observational, open-label cohort study conducted on 34 CM patients under OBT-A treatment, selected between December 2016 and December 2017, who agreed to download a smartphone headache diary application (Aid Diary) according to the study instructions. The analysis was conducted using the smartphone application data reports on allodynia, intensity and extension of pain, and vegetative symptoms. We analysed a total of 707 records of single migraine attacks reported by compliant users (n = 34) in real-time. OBT-A significantly reduced allodynia, the number of vegetative symptoms, pain extension and intensity in single migraine attacks. Pain intensity was correlated with pain extension. In single migraine attacks, OBT-A improved symptoms of central sensitization. This action could be exerted by modulating nociceptive transmission and reducing the burden of single migraine episodes and improving the overall quality of life.

show abstract

“…The MSQv2 has three HRQoL dimensions: RR, RP, and EF [22]. The RR dimension has seven items and measures migraine impact on normal activities such as work, productivity, daily activities, energy, tiredness, concentration, leisure, and relationships [14,23]. The RP dimension has four items and measures the impact of migraine on interrupting performance of normal activities [14].…”

Section: Description Of Msqv2mentioning

confidence: 99%

“…The EF dimension has three items and measures migraine's effect on emotional function [14]. The questionnaire consists of 14 questions about migraine attacks during the past 4 weeks, with six response options at each question, ranging from 1 to 6 (1, none of the time; 2, a little bit of the time; 3, some of the time; 4, a good bit of the time; 5, most of the time; and 6, all of the time), and scored linearly on a 0-100 scale where higher scores indicate better HRQoL [23,24]. The minimum clinically important difference for within-group analyses are 5 points, 5-7.9 points, and 8-10.6 points for RR, RP, and EF, respectively [25].…”

Section: Description Of Msqv2mentioning

confidence: 99%

Mapping Migraine-Specific Quality of Life to Health State Utilities in Patients Receiving Rimegepant

et al. 2021

View full text Add to dashboard Cite

Introduction: Migraine is a debilitating neurological condition, affecting up to 15% of Americans. Recent estimates from a long-term safety study of rimegepant showed evidence of decreased monthly migraine days (MMD) in people with episodic migraine treated with rimegepant 75 mg. The objective of this study was to characterize migraine-specific quality of life version 2.1 (MSQv2) scores and corresponding mapped EuroQol-5 Dimensions-3 Level (EQ-5D-3L) utility values. Methods: Study participants were randomized into two treatment regimens: individuals with 2-14 MMD received rimegepant 75 mg as needed (PRN), and those with 4-14 MMD at baseline who received rimegepant on a fixed everyother-day schedule plus an as needed dose on

show abstract

Content validity of the Migraine-Specific Quality of Life Questionnaire version 2.1 electronic patient-reported outcome

Cited by 13 publications

References 26 publications

Systematic Review of the Effect of a One-Day Versus Seven-Day Recall Duration on Patient Reported Outcome Measures (PROMs)

Systematic Review of the Effect of a One-Day Versus Seven-Day Recall Duration on Patient Reported Outcome Measures (PROMs)

Effects of Botulinum Toxin on Migraine Attack Features in Chronic Migraine: A Six-Month Open-Label Observation Study through Electronic Diary Smartphone Application

Mapping Migraine-Specific Quality of Life to Health State Utilities in Patients Receiving Rimegepant

Contact Info

Product

Resources

About